News Archive

The DCRI’s Michael Pencina, PhD, and Sheng Luo, PhD, discussed the design of two new Phase 3 clinical trials testing a potential treatment for coronavirus.

A focus on building a nationwide system of real-world data could provide the opportunity for more randomized clinical trials to generate needed evidence to inform health care decisions.

Findings from a DCRI-led study recently published in JAMA Internal Medicine suggest new prognostic implications for patients who have abnormal exercise electrocardiography (ECG) but normal stress echocardiography (Echo) results. In clinical practice, exercise ECG is combined with stress Echo imaging for the evaluation of coronary artery disease. Although it is not uncommon for patients to have discordant results (abnormal ECGs and normal Echos), it was previously unclear whether this had any prognostic significance for these patients. An observational study led by DCRI’s Melissa Daubert, MD, sought to answer this question.

Neither prescription volume nor approval rates for PCSK9 inhibitors increased following the release of results from two large outcomes trials that demonstrated safety and effectiveness of this nove

In a recent editorial, DCRI faculty call for improved heart failure trial enrollment, as well as modifications to the infrastructure used to evaluate whether treatments work in real-world settings.

Two DCRI researchers contributed to a study that points to a potential early warning sign for increased risk of cardiovascular disease.

A recent study led by the DCRI leveraged real-world data to shed new light on resuscitation for patients on maintenance dialysis when they experience in-hospital cardiac arrest.

Evidence from a recently completed DCRI-led clinical trial supports the hypothesis that an investigational digital therapeutic may be an effective treatment for children with ADHD.

The EXSCEL trial, which explored the impact of exenatide on major cardiovascular events in patients with Type 2 diabetes, has also published nearly a dozen secondary manuscripts on a range of topic

In response to a recent study that found the majority of cardiovascular patients are eligible for at least one of 12 novel secondary prevention therapies, representatives from the DCRI urge a focus on implementation of these therapies into clinical practice. The wide range of new therapies for cardiovascular secondary prevention raises questions about the best way to use these therapies in clinical practice and underscores the need for novel approaches to implement these therapies into routine patient care.